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Purpose: To identify the optimal combination of pharmacokinetic model and arterial input function (AIF) for quantitative
analysis of blood perfusion in the patellar bone using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Materials and Methods: This method design study used a random subset of five control subjects from an Institutional
Review Board (IRB)-approved case–control study into patellofemoral pain, scanned on a 3T MR system with a contrast-
enhanced time-resolved imaging of contrast kinetics (TRICKS) sequence. We systematically investigated the reproduc-
ibility of pharmacokinetic parameters for all combinations of Orton and Parker AIF models with Tofts, Extended Tofts
(ETofts), and Brix pharmacokinetic models. Furthermore, we evaluated if the AIF should use literature parameters, be
subject-specific, or group-specific. Model selection was based on the goodness-of-fit and the coefficient of variation of
the pharmacokinetic parameters inside the patella. This extends previous studies that were not focused on the patella
and did not evaluate as many combinations of arterial and pharmacokinetic models.
Results: The vascular component in the ETofts model could not reliably be recovered (coefficient of variation [CV] of vp
>50%) and the Brix model parameters showed high variability of up to 20% for kel across good AIF models. Compared
to group-specific AIF, the subject-specific AIF’s mostly had higher residual. The best reproducibility and goodness-of-fit
were obtained by combining Tofts’ pharmacokinetic model with the group-specific Parker AIF.
Conclusion: We identified several good combinations of pharmacokinetic models and AIF for quantitative analysis of
perfusion in the patellar bone. The recommended combination is Tofts pharmacokinetic model combined with a group-
specific Parker AIF model.
Level of Evidence: 2
Technical Efficacy: Stage 1
J. MAGN. RESON. IMAGING 2018;47:848–858.
Research suggests that altered blood perfusion of thepatellar bone may play a role in the pathogenesis of
patellofemoral pain (PFP), a common knee complaint.1–8
Blood perfusion can be visualized and analyzed quantita-
tively using dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI).9 Despite the well-described use of DCE-
MRI for a variety of indications such as tumors and cerebral
strokes,10,11 only a limited number of publications address
DCE-MRI in bone,12–16 and none specifically in the patella.
DCE-MRI in bone has been limited due to the sparse vascular-
ization of bone and the typical low contrast enhancement
compared to surrounding tissues.12,16 The mobility of the
patella poses an additional specific challenge.
Signal intensity changes in the DCE-MRI time series
are due to the contrast medium entering the tissue through
feeding arteries, residing in the extravascular space, and sub-
sequent draining. This process can be studied semiquantita-
tively using measures like time-to-peak, or quantitatively by
fitting a pharmacokinetic model to the DCE-MRI data to
extract truly quantitative measures of perfusion.9 Quantitative
DCE-MRI requires choosing one of multiple proposed arte-
rial input functions (AIFs) and one of the pharmacokinetic
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models that together are able to describe the dynamic contrast
concentration. Selection of appropriate models is especially rel-
evant for low signal intensity regions since a too complex
model (too many degrees of freedom) will be influenced
stronger by acquisition noise and, hence, is less sensitive to
between-group or between-subject differences in perfusion.
Moreover, a model that cannot describe the DCE-MRI signal
with sufficient accuracy may fail to detect relevant changes in
perfusion. Although quantitative DCE-MRI has been per-
formed in several bones,9 no thorough evaluation of the opti-
mal combination of AIF and a pharmacokinetic model has
been presented. Due to the differences in perfusion, the model
evaluation results obtained on tumor tissue are not directly
applicable to the analysis of patellar perfusion.17
The aim of this study was to identify the optimal
combination of pharmacokinetic model and AIF for quanti-
tative analysis of perfusion in the patellar bone using DCE-
MRI. As potentially appropriate AIF models we selected
three models by Orton et al18 and several parametrizations
of Parker et al’s model.19 As pharmacokinetic models we




This method design study used a random subset of five control
subjects and five patients from an Institutional Review Board
(IRB)-approved case–control study into patellofemoral pain con-
taining 134 subjects.21 All subjects provided written informed con-
sent. A 3T MRI scanner (Discovery MR750, GE Healthcare,
Milwaukee, WI) with a dedicated 8-channel knee coil (Invivo,
Gainesville, FL) was used.
DCE-MRI was acquired by a time-resolved imaging of con-
trast kinetics (TRICKS) sequence with anterior–posterior (AP) fre-
quency encoding direction to avoid pulsation artifacts of the
popliteal artery into the region of interest. MRI parameters were:
in-plane pixel resolution 1.5 mm, slice thickness 5 mm, field of
view 380 3 380 3 70 mm, acquisition matrix 256 3 128, 14
sagittal slices, 70% sampling in the phase direction, echo time
(TE) 5 1.7 msec, repetition time (TR) 5 9.3 msec, flip angle
(FA) 5 308. The DCE-MRI protocol consisted of 35 phases of
10.30 6 0.07 sec (constant within subject). Intravenous contrast
administration of 0.2 mmol/kg gadopentetate dimeglumine (Mag-
nevist, Bayer, Berlin, Germany), at a rate of 2 ml/s, was started
after the first phase. Additionally, a nonfat-suppressed 3D SPGR
sequence with in-plane resolution of 0.3 3 0.3 mm and 0.5 mm
slices was acquired before contrast administration for delineation of
the patellar bone marrow. See Figs. 1 and 2 for an example image
of a control subject and a patient, respectively.
Motion Compensation
Image-driven motion compensation was applied, based on a tech-
nique developed for T1 mapping in femoral and tibial articular car-
tilage.22 A registration mask was drawn around the patella in the
3D SPGR image. Within this mask the DCE-MRI time series
were automatically registered to the first DCE-MRI timepoint
FIGURE 1: Example DCE image at maximum arterial enhancement in one of the control subjects, time intensity curve, and fit with
Tofts’ model, including the overlays showing the apparent heterogeneity inside the patella.
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using a rigid transformation model. Subsequently, the first phase
was registered to the 3D SPGR image and all DCE-MRI scans
were transformed to the grid of the high-resolution 3D SPGR.
Visual inspection indicated successful alignment of the time series.
Quantitative DCE-MRI Modeling
The dynamic DCE-MRI signal in each voxel A(t) is described by a
combination of three models: The AIF, the pharmacokinetic
response function (P), and the function that relates contrast con-






where  denotes convolution and n,v,u are model parameters.
For the AIF model we evaluated three computationally
efficient models of Orton et al18 (Orton1, Orton2, Orton3), five
variations on Parker et al’s model19 with increasing degrees of free-
dom (Parker-L, Parker-A, Parker-S, Parker-E, Parker-T), as well as
a “dummy” triangle-shaped AIF function. The AIF parameters v
were estimated from a manually outlined arterial region, either
from a single subject (subject-specific) or from the entire group of
subjects (group-specific), or obtained from the literature (literature-
based).
For the pharmacokinetic model P we evaluate Brix, Tofts,
and Extended Tofts (ETofts) models.20,23 The Brix model has AH,
kep, and kel as parameters u, while Tofts model has Ktrans and kep as
u, and ETofts adds vp to it; each model additionally includes a
delay parameter.
For S we used a standard model suitable for the SPGR based
sequence with one free parameter n 5 S0.
The Supplementary Material sections S.1–S.3 provide more
details on the models and section S.4 provides details on the maxi-
mum likelihood estimation method used to recover n, v, and u
with constraints provided in Table 1.
Technical Validation on Phantom Data
To validate the model fitting method, a simulated dataset from a
DCE-MRI anthropomorphic digital reference phantom was used.24
This phantom, designed to validate fitting methods, contains a
simulation of perfusion inside a brain tumor, which was selected as
the volume-of-interest (VOI). All AIF models were fitted on
selected arterial voxels and evaluated with the R-square value. Sub-
sequently, these AIFs were used to analyze the provided VOI with
ETofts. Accuracy of the pharmacokinetic parameters was measured
by the median absolute difference (MAD) between the estimated
and ground truth parameters of the ETofts model in the VOI and
compared to the median ground truth value.
Comparative Evaluation of AIF Models
The AIF models were fitted to the voxels in a region of interest
(ROI) drawn in the center of the popliteal artery, approximately at
the level of the center of the patella. This artery was the largest
artery in the field of view and could easily be identified in all sub-
jects. Fit quality was evaluated by Akaike’s information criterion
(AIC)25,26:
FIGURE 2: Example DCE image at maximum arterial enhancement in one of the patients, time intensity curve, and fit with Tofts’
model, including the overlays showing the apparent heterogeneity inside the patella.
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AIC52k1nlnðSSRÞ (2)
where k is the number of parameters in the model (for all sub-
jects), n is the number of samples to which the model is fitted,
and SSR is the sum of squared residuals (measurements minus val-
ues predicted by the fitted model). AIC provides an objective way
to compare models with different complexities. Since the voxels
from which the AIF is estimated are selected from a small region,
they have substantial spatial correlation, which reduces the effective
number of degrees of freedom. To avoid a biased model selection
due to these correlations, we evaluated the AIC on one randomly
selected voxel within the arterial ROI of each subject, and we
report the mean and standard deviation of the AIC over 1000 ran-
dom selections.
Comparative Evaluation of Pharmacokinetic
Models
Each combination of AIF and pharmacokinetic model was fitted to
the DCE-MRI data. For each pharmacokinetic parameter we com-
puted its weighted mean over a VOI consisting of the patellar
bone marrow, drawn by an experienced observer (R.H.). As
weights we used 1/CRLB where CRLB is the Cramer-Rao lower
bound at each voxel, which is a measure of fit uncertainty (see
Supporting Information S.4). In this way, we suppress the influ-
ence of voxels with an unreliable fit. The mean and coefficient of
variation (CV 5 standard deviation / jmeanj) across subjects were





was computed to evaluate goodness-of-fit.
TABLE 1. Parameters, Units, and Constraints Applied During Estimation
Model All Tofts and ETofts ETofts Brix
parameter delay Ktrans kep vp AH kep kel
unit min (min)-1 (min)-1 (fraction) min-2 (min)-1 (min)-1
Lower bound optimization 0 -0.1 -1 -0.1 -0.2 -1 0
Lower bound initialization 0.17 -0.01 -0.2 -0.001 -0.05 -0.2 0.2
Upper bound initialization 2.50 0.5 0.5 0.001 0.25 0.8 4
Upper bound optimization 5 1 3 0.2 1 3 10
TABLE 2. Median Absolute Difference (MAD) of ETofts Parameters in the VOI of the Phantom Experiment for
the Different AIF Models
Ktrans (1/min) kep (1/min) vp (fraction)
Literature-based
Triangle 0.1986 0.345 0.0155
Orton1 0.0696 0.459 0.0111
Orton2 0.0672 0.466 0.0059
Orton3 0.0081 0.446 0.0074
Parker 0.0133 0.468 0.0079
Subject-specific
Triangle 0.5461 0.387 0.0379
Orton1 0.0696 0.459 0.0111
Orton2 0.0695 0.032 0.0126
Orton3 0.0293 0.043 0.0107
Parker-A 0.0118 0.082 0.0092
Parker-S 0.0059 0.070 0.0047
Parker-E 0.0096 0.085 0.0058
Parker-T 0.0079 0.086 0.0011
Median ground truth 0.0701 0.418 0.0138
Median ground truth values are given in the bottom row.
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FIGURE 3: Literature-based, subject-specific, and group-specific arterial contrast concentration, from left to right, top to bottom:
Literature, Orton1, Orton2, Orton3, Parker-A, Parker-S, Parker-E, Parker-T. In each figure, the group-specific estimate is shown by
the black bold line.
TABLE 3. Mean (SD) of the AIC of AIF Fits
Literature-based Subject-specific Group-specific
Triangle 2636.0 (14.6) 1999.8 (14.2) 1987.9 (13.3)
Orton1 1906.7 (21.6) 1365.6 (12.3) 1346.9 (15.1)
Orton2 1963.2 (10.9) 560.8 (21.5) 751.8 (38.0)
Orton3 1308.5 (17.3) 605.9 (19.6) 793.5 (33.8)
Parker-L 1348.8 (16.1)
Parker-A 576.6 (24.4) 756.1 (35.8)
Parker-S 454.4 (36.5) 725.4 (42.2)
Parker-E 244.7 (52.6) 662.0 (47.9)
Parker-T 297.3 (54.6) 640.2 (53.8)
Lower values indicate a better model fit.
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RESULTS
Technical Validation on Phantom Data
On the phantom data, the Parker-T model fitted best to the
arterial signal with an R-square value of 0.9994, whereas
Parker-E and Orton3 had R-square of 0.9983 and 0.9876,
respectively. Orton3 fitted best among the Orton models.
See Table 2 for the MAD of Ktrans, kep, and vp inside the
VOI. Parker-T had the lowest MAD for Ktrans and vp.
Comparative Evaluation of AIF Models
Figure 3 shows the AIFs that were estimated by the different
models. There were substantial differences between AIFs
when estimated for each subject individually, especially for
the models Orton2, Orton3, and Parker-A. The substantial
differences in contrast concentration in the tail of the curve
were observed to be correlated to under/overestimation of
the baseline signal intensity n. For subject-specific Parker-E
and Parker-T, the first-pass contrast concentration differed
substantially from the group-specific first-pass and the first-
pass as provided by the literature-based AIFs. The group-
specific Parker-T was also substantially different from the
literature-based Parker model.
Table 3 shows the mean and standard deviation of the
AIC value of the AIF fits over the 1000 random selections
of one voxel per subject. Note that in Eq. (2), n 5 175 (35
timepoints 3 1 randomly selected voxel 3 5 subjects) and
k varies between 20 (literature-based AIF; only estimating
delay and n per subject) and 123 (subject-specific Parker-T).
TABLE 4. For Each AIF and Pharmacokinetic Model, the Mean Over the Five Control Subjects of Each Parameter
and the Residual
Tofts Extended Tofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature-based
Triangle 0.057 20.133 0.050 20.139 0.000 0.127 0.023 0.464 0.119 0.119 0.070
Orton1 0.023 0.112 0.021 0.116 0.000 0.059 0.255 1.415 0.083 0.081 0.069
Orton2 0.025 0.123 0.021 0.125 0.000 0.062 0.284 1.407 0.081 0.081 0.069
Orton3 0.016 0.148 0.014 0.151 0.000 0.035 0.215 1.430 0.079 0.079 0.069
Parker 0.015 0.131 0.014 0.134 0.000 0.037 0.313 0.954 0.081 0.081 0.069
Subject-specific
Triangle 0.770 20.157 0.756 20.163 0.050 0.924 0.009 0.249 0.146 0.147 0.114
Orton1 0.035 0.211 0.029 0.203 0.004 0.057 0.234 2.148 0.074 0.073 0.073
Orton2 0.014 0.106 0.013 0.041 0.000 0.029 0.246 1.594 0.084 0.074 0.070
Orton3 0.005 0.095 0.005 0.097 0.000 0.011 0.229 1.306 0.085 0.086 0.068
Parker-A 0.008 0.127 0.007 0.131 0.000 0.017 0.254 1.195 0.084 0.084 0.069
Parker-S 0.015 0.160 0.013 0.161 0.000 0.032 0.210 1.259 0.080 0.079 0.069
Parker-E 0.015 0.191 0.013 0.193 0.000 0.030 0.233 1.856 0.076 0.076 0.069
Parker-T 0.014 0.177 0.012 0.180 0.000 0.030 0.250 1.664 0.077 0.077 0.068
Group-specific
Triangle 0.752 20.139 0.734 20.145 0.053 0.883 20.056 0.488 0.132 0.132 0.105
Orton1 0.031 0.219 0.025 0.207 0.004 0.050 0.296 1.724 0.074 0.072 0.073
Orton2 0.020 0.212 0.017 0.213 0.000 0.041 0.302 1.589 0.075 0.075 0.069
Orton3 0.004 0.071 0.004 0.075 0.000 0.008 0.155 1.198 0.088 0.089 0.068
Parker-A 0.007 0.136 0.007 0.139 0.000 0.015 0.199 1.212 0.080 0.079 0.069
Parker-S 0.015 0.197 0.014 0.198 0.000 0.032 0.262 1.367 0.076 0.076 0.069
Parker-E 0.014 0.187 0.012 0.189 0.000 0.028 0.236 1.490 0.075 0.075 0.069
Parker-T 0.014 0.181 0.011 0.184 0.000 0.027 0.230 1.799 0.076 0.076 0.069
Ktrans, kep, kel in 1/min; vp is a fraction; AH is in 1/min
2; residual norm is in arbitrary units but it can be compared across all model
combinations.
Poot et al.: DCE MRI of the Patella
March 2018 853
The AIC of Parker-E and Parker-T were much lower than
the AIC of the Orton models. All models substantially
improved over the triangle AIF.
Comparative Evaluation of Pharmacokinetic
Models
Tables (4–7) show the mean and CV across control subjects
and across patients of the pharmacokinetic parameters, as
well as of the residual norm, for all combinations of AIF
and pharmacokinetic models.
Variations in parameter values for different AIF mod-
els were observed, both for controls (Table 4) and patients
(Table 6); eg, 20% difference in Brix kel between group-
specific Parker E&T. The residual of ETofts was not sub-
stantially lower than the residual of Tofts, which indicates
that, in our patellar VOI, inclusion of the vascular compo-
nent did not lead to a better fit. This is additionally
reflected in that the vascular fraction vp is close to zero. For
most AIF models, the residual of the Brix model was 10%
lower than the residual of Tofts and ETofts. The residual
norm did not vary substantially across AIF models, except
for the “dummy” Triangle AIF and the literature-based AIFs
combined with the ETofts model, which resulted in a higher
residual norm.
Table 5 shows that for the control subjects the pharma-
cokinetic parameters estimated with subject-specific AIF mod-
els had an increased CV compared to pharmacokinetic
parameters estimated with literature-based and group-specific
AIF models. For most combinations there were only small
differences in CV of the parameters between literature-based
TABLE 5. For Each AIF and Each Parameter of the Pharmacokinetic Models, the CV (%) Over the Five Control
Subjects
Tofts Extended Tofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature-based
Triangle 62.9 231.4 70.0 220.1 82.2 23.9 492.7 79.1 20.5 20.7 14.9
Orton1 35.5 27.3 52.4 26.5 2165.5 30.7 43.5 61.9 16.5 16.4 15.9
Orton2 35.6 24.5 48.7 23.2 436.8 35.7 61.0 60.8 15.9 16.5 15.8
Orton3 32.4 23.9 40.0 22.8 2249.6 32.8 28.4 50.0 15.9 16.2 16.2
Parker 36.8 24.0 45.4 23.9 188.0 31.5 41.7 73.9 16.2 16.4 16.1
Subject-specific
Triangle 32.9 216.4 34.5 214.3 77.3 6.8 1120.1 127.8 25.4 25.2 23.4
Orton1 23.7 27.3 36.8 28.9 61.4 28.4 26.0 31.6 15.3 15.3 16.1
Orton2 57.1 223.2 53.3 950.9 636.6 60.5 32.4 47.7 35.7 15.9 16.1
Orton3 52.5 40.9 53.9 39.8 2514.8 45.6 76.9 44.3 16.6 17.0 16.7
Parker-A 53.2 53.1 46.1 50.1 249.9 58.8 51.5 51.8 18.6 19.7 16.2
Parker-S 53.8 79.3 52.9 79.3 3897.8 49.5 69.4 60.1 17.2 17.4 15.9
Parker-E 19.7 25.5 27.6 25.3 199.9 24.1 32.0 20.0 17.5 18.2 15.2
Parker-T 27.3 22.5 31.1 21.7 583.9 28.1 28.8 31.9 16.6 17.1 15.9
Group-specific
Triangle 23.2 218.8 25.5 216.9 78.8 8.8 2108.3 43.3 24.7 24.4 22.6
Orton1 26.2 16.8 38.4 17.9 56.8 29.6 43.8 62.3 15.3 15.2 15.9
Orton2 27.6 20.2 43.3 19.3 2420.5 32.2 28.0 44.8 15.7 16.0 15.7
Orton3 33.8 56.3 40.4 53.0 335.0 29.3 43.1 46.7 18.4 18.8 16.5
Parker-A 34.3 28.7 40.4 28.2 497.9 31.7 34.2 48.5 16.6 17.0 16.5
Parker-S 28.8 21.1 38.8 20.1 2713.5 32.4 32.9 54.6 15.9 16.2 16.2
Parker-E 29.3 22.8 42.0 22.1 8001.0 32.4 25.6 45.3 15.3 15.7 15.4
Parker-T 29.3 23.3 44.2 22.7 21748.7 32.1 27.8 19.8 15.4 15.9 15.5
The three right-most columns show the CV of the residual.
Journal of Magnetic Resonance Imaging
854 Volume 47, No. 3
and group-specific AIF models. The exceptions were kep of
Tofts and ETofts with Orton3, vp of ETofts, and kep and kel
of Brix with Orton2, Orton3, and Parker, which were mostly
found to have a higher CV for the group-specific AIF. When
comparing the CV of the different models we noted that over-
all the CV for the Tofts’ model was lower than the CV for
the other models. Especially, the CV of Ktrans was substantially
larger in ETofts than Tofts. For ETofts, the CV of vp was very
high, demonstrating that the vascular component could not
be precisely recovered, caused by the close to zero vp (Table
4). The CV of the Brix model parameters was, overall, higher
than the CV of the Tofts model parameters. The CV in
patients (Table 7) was higher than in control subjects.
Discussion
This article presents a systematic comparative evaluation of
AIF and pharmacokinetic models for quantitatively analyz-
ing patellar perfusion with DCE-MRI.19 Below, we derive
several recommendations based on our results, and discuss
the strengths, limitations, and impact.
The evaluation of digital phantom data shows that the
proposed fitting method can accurately recover pharmacoki-
netic parameters when a correct AIF model is used. Although
this phantom dataset simulates tumor perfusion,24 which dif-
fers from patellar perfusion, the comparison with the ground
truth confirms the technical validity of the proposed fitting
methods.
TABLE 6. For Each AIF and Pharmacokinetic Model, the Mean Over the Five Patients of Each Parameter and the
Residual
Tofts Extended Tofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature-based
Triangle 0.063 20.159 0.050 20.166 0.000 0.212 20.034 0.803 0.163 0.161 0.091
Orton1 0.021 0.093 0.018 0.102 0.000 0.121 0.233 1.740 0.107 0.104 0.088
Orton2 0.023 0.109 0.020 0.114 0.000 0.138 0.171 2.095 0.105 0.103 0.089
Orton3 0.014 0.133 0.013 0.135 0.000 0.073 0.276 2.138 0.100 0.100 0.086
Parker 0.013 0.112 0.012 0.115 0.000 0.075 0.214 1.818 0.103 0.104 0.086
Subject-specific
Triangle 0.652 20.220 0.545 20.227 0.081 0.874 20.072 0.243 0.290 0.290 0.232
Orton1 0.030 0.207 0.024 0.193 0.007 0.290 0.215 2.132 0.101 0.097 0.106
Orton2 0.019 0.201 0.017 0.201 0.001 0.111 0.229 1.837 0.094 0.093 0.091
Orton3 0.004 0.037 0.003 0.035 0.000 0.017 0.098 1.607 0.127 0.126 0.085
Parker-A 0.003 0.039 0.003 20.002 0.000 0.017 0.118 1.523 0.125 0.118 0.085
Parker-S 0.012 0.170 0.011 0.167 0.000 0.058 0.211 2.118 0.097 0.096 0.086
Parker-E 0.011 0.159 0.009 0.157 0.000 0.049 0.200 1.552 0.097 0.095 0.085
Parker-T 0.010 0.155 0.009 0.151 0.001 0.051 0.259 2.023 0.099 0.097 0.085
Group-specific
Triangle 0.630 20.193 0.577 20.203 0.088 0.851 0.038 0.180 0.280 0.279 0.224
Orton1 0.029 0.217 0.023 0.202 0.007 0.293 0.221 2.335 0.101 0.097 0.106
Orton2 0.018 0.198 0.016 0.198 0.001 0.091 0.229 2.224 0.093 0.091 0.088
Orton3 0.004 0.048 0.003 0.051 0.000 0.015 0.105 1.535 0.110 0.110 0.083
Parker-A 0.006 0.117 0.006 0.119 0.000 0.029 0.164 1.742 0.097 0.097 0.084
Parker-S 0.014 0.184 0.012 0.183 0.001 0.068 0.219 2.269 0.093 0.093 0.087
Parker-E 0.013 0.170 0.011 0.171 0.001 0.058 0.202 2.155 0.092 0.091 0.086
Parker-T 0.012 0.164 0.011 0.165 0.000 0.055 0.255 1.881 0.092 0.091 0.085
Ktrans, kep, kel in 1/min; vp is a fraction; AH is in 1/min
2; residual norm is in arbitrary units but it can be compared across all model
combinations.
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As indicated by the AIC scores, Triangle and Orton1
do not model the arterial signal well. For the Parker model,
the increase in complexity from Parker-A to Parker-E is sup-
ported by the measured imaging data, since Parker-E leads
to substantially improved arterial fits, reflected by lower
AIC. This indicates that our addition of a persisting contrast
concentration to the Parker-E model was justified. Overall,
in terms of AIC, the most competitive models are Orton2,
Parker-E, and Parker-T.
The AIC score shows substantially improved arterial
fits of the subject and group-specific AIFs compared to the
literature-based AIF. Moreover, except for Orton3, the
literature-based AIFs lead to higher residuals when used in
combination with the (E)Tofts pharmacokinetic model.
Based on these results, we recommend against using a
literature-based AIF.27
Since the large intersubject variability in the shape of
the first-pass contrast concentration for subject-specific AIF
modeling with Parker-E and Parker-T, and to a lesser extent
with Orton2 and Orton3, cannot be explained biologically,
similar to Ref. 28, the group-specific AIF is preferred for
these models, despite the higher AIC value. Note that for
Parker-E&T the CV of Ktrans and AH is higher for the
group-specific AIF than for the subject-specific AIF, while it
is lower for kep. This suggests that components of the AIF
relevant for determining Ktrans can be recovered from an
individual subject with a higher precision than the intersub-
ject variation, whereas those components more relevant to
determine kep cannot.
Comparing pharmacokinetic models, the CV typically
is lowest for Tofts. This is probably due to the larger num-
ber of parameters in ETofts and Brix. The larger number of
TABLE 7. For Each AIF and Each Parameter of the Pharmacokinetic Models, the CV (%) Over the Five Patients
Tofts Extended Tofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature-based
Triangle 107.8 240.6 108.9 233.1 93.2 70.0 2409.6 50.2 46.4 46.2 25.4
Orton1 84.3 99.6 94.6 88.7 2120.9 85.1 18.0 58.8 25.6 24.8 23.2
Orton2 83.9 89.1 92.8 84.1 2175.4 89.3 76.4 31.4 24.5 24.2 23.2
Orton3 87.1 76.6 92.7 75.6 2356.5 87.1 29.9 49.4 22.7 23.0 22.3
Parker 91.2 86.5 94.1 83.3 359.9 85.4 24.5 68.0 24.0 24.1 22.6
Subject-specific
Triangle 52.9 240.5 71.2 236.9 88.7 16.1 2199.9 67.1 83.7 83.5 80.8
Orton1 69.1 65.5 94.4 64.1 96.2 116.3 67.6 38.5 24.2 23.0 32.6
Orton2 100.9 71.9 119.3 70.9 140.8 128.4 75.7 72.4 20.7 20.4 25.4
Orton3 153.4 456.9 154.0 474.1 123.3 141.7 178.2 67.5 41.1 42.4 23.5
Parker-A 110.5 384.5 118.6 29638.5 150.9 88.3 140.4 51.7 26.1 30.4 23.0
Parker-S 79.4 86.1 93.9 90.4 159.2 78.8 85.6 38.1 20.5 20.4 23.0
Parker-E 83.8 89.7 101.8 94.0 151.7 79.3 84.4 67.9 20.4 20.1 22.7
Parker-T 83.9 87.6 102.2 93.0 108.5 77.0 20.9 54.4 17.0 16.9 23.0
Group-specific
Triangle 51.0 239.5 64.0 236.3 76.4 17.0 328.8 84.6 90.1 89.7 84.3
Orton1 74.0 54.1 94.5 53.5 80.5 119.4 54.0 28.5 24.2 23.2 31.7
Orton2 81.2 59.2 94.4 58.8 91.5 94.8 62.0 32.3 21.8 21.6 22.6
Orton3 91.2 175.7 96.0 165.3 22921.1 78.2 114.0 41.3 26.4 26.8 22.5
Parker-A 87.4 83.2 94.9 81.8 107.7 82.9 77.2 57.1 21.8 22.0 22.6
Parker-S 82.7 61.9 94.6 61.9 72.8 90.8 63.6 35.6 21.5 21.6 22.4
Parker-E 83.8 64.0 95.1 64.0 81.9 88.8 66.1 39.6 21.3 21.4 21.8
Parker-T 84.4 65.5 94.1 65.5 70.9 88.1 82.3 57.9 21.2 21.4 21.9
The three right-most columns show the CV of the residual.
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parameters in Brix may also explain the 10% lower residual
compared to Tofts. As all three pharmacokinetic models
explain a similar fraction of the DCE-MRI signal, we expect
that group differences, eg, between cases and controls, in
perfusion cause similar relative changes in parameter values.
This implies that the model with the smallest CV (Tofts)
will likely be more sensitive to detect group differences than
the other models (ETofts, Brix).
We chose to aggregate the voxel-wise pharmacokinetic
measures by computing a weighted mean over the patella
VOI. Any spatial heterogeneity within the patella is thus
averaged out. Hence, it should be noted that using these
measures to study group differences implicitly assumes non-
localized physiological changes in the patella.
As no in vivo ground truth values for pharmacokinetic
parameters are available, we could not base model selection
on closeness to ground truth, and this implies that reliable
absolute quantification of perfusion values currently cannot
be claimed. As in Schmid et al,17 we used a statistical analy-
sis method to trade off model complexity against goodness-
of-fit, in order to guide model selection. Note that, com-
pared to Schmid et al, we evaluated a wider range of mod-
els, both for AIF and for pharmacokinetic model, and
applied it to patellar DCE-MRI data.
The substantial differences in pharmacokinetic param-
eters obtained with different AIFs emphasize the relevance
of choosing a good AIF model. Severe bias in parameters
could occur with a suboptimal AIF. The small differences
observed among the best candidates indicate that potentially
other combinations can be best for acquisitions with differ-
ent settings and/or in different body parts; even for other
bones. Hence, our proposed framework for evaluating perfu-
sion is an important contribution in itself. It allowed identi-
fication of a few combinations of AIF models and
pharmacokinetic models that performed well in all aspects:
AIC score and biological credibility of the AIF, CV of phar-
macokinetic parameters, and goodness-of-fit in the patella
VOI. Given the similarity in perfusion mechanisms and
MR characteristics, we would expect these combinations to
also perform well when studying perfusion in other bones
such as tibia,12 femur,16 hip,14 or bony pelvis.15
Although Orton2 combined with the Tofts’ model
seems to slightly improve reproducibility and goodness-of-fit
in this dataset, we consider the lower AIC score of Parker-T
as well as the improved biological credibility of that AIF to
be more important. Together with the accuracy of this com-
bination on phantom data, this gives good confidence that
group-specific Parker-T combined with the Tofts’ model is
suitable to identify patellar perfusion abnormalities.
The observed values of the CV indicate that with a
consistently used combination of models, reproducibility is
sufficient to allow identification of group differences in perfu-
sion with reasonably sized groups; eg, 40 subjects per group
allow identification of group differences of 10% in Ktrans or
kep at a significance level of P < 0.05 with 75% power.
In conclusion, the most suitable choice of models for
the analyzed patellar DCE-MRI data is Parker’s arterial
input model, where all parameters of Parker’s model are esti-
mated from arterial voxels of the full group of subjects,
combined with Tofts’ pharmacokinetic model.
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